Markets:

Overview

News

Currencies

International

Treasuries

Collegium Pharmaceutical, Inc. - Common Stock (NQ:COLL)

45.77 +0.49 (+1.08%)

Streaming Delayed Price Updated: 10:37 AM EST, Feb 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Collegium Pharmaceutical, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >

Branded Pharmaceuticals Stocks Q2 Highlights: Collegium Pharmaceutical (NASDAQ:COLL)

September 24, 2025

The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Collegium Pharmaceutical...

Via StockStory

Topics Artificial Intelligence Intellectual Property

1 Safe-and-Steady Stock to Keep an Eye On and 2 Facing Headwinds

September 12, 2025

A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance. Investors who prioritize stability may miss out on higher-reward opportunities elsewhere.

Via StockStory

1 Stock Under $50 Worth Investigating and 2 We Ignore

August 13, 2025

Stocks in the $10-50 range offer a sweet spot between affordability and stability as they’re typically more established than penny stocks. But their headline prices don’t guarantee quality, and...

Via StockStory

3 Profitable Stocks We Think Twice About

August 12, 2025

Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow.

Via StockStory

Earnings Scheduled For August 7, 2025 ↗

August 07, 2025

Via Benzinga

Earnings Scheduled For May 8, 2025 ↗

May 08, 2025

Via Benzinga

Earnings Scheduled For February 27, 2025 ↗

February 27, 2025

Via Benzinga

COLL Q2 Deep Dive: Jornay Expansion Drives Revenue Guidance Increase, Margins Face Investment Pressure

August 12, 2025

Pharmaceutical company Collegium Pharmaceutical (NASDAQ:COLL) reported Q2 CY2025 results topping the market’s revenue expectations, with sales up 29.4% year on year to $188 million. The company’s...

Via StockStory

Collegium Pharmaceutical (NASDAQ:COLL) Exceeds Q2 Expectations, Stock Jumps 10.2%

August 07, 2025

Pharmaceutical company Collegium Pharmaceutical (NASDAQ:COLL) reported Q2 CY2025 results beating Wall Street’s revenue expectations, with sales up 29.4% year on year to $188 million. The company’s...

Via StockStory

Collegium (COLL) Q2 Revenue Jumps 29% ↗

August 07, 2025

Via The Motley Fool

Topics Intellectual Property

Collegium Pharmaceutical Inc (NASDAQ:COLL) Reports Record Q2 2025 Earnings and Raises Full-Year Guidance ↗

August 07, 2025

Collegium Pharmaceutical (COLL) reports strong Q2 2025 earnings, beating estimates with $188M revenue (+29% YoY) and $1.68 EPS. Raised full-year guidance and new $150M buyback program signal growth...

Via Chartmill

Collegium Pharmaceutical (COLL) Q2 Earnings: What To Expect

August 05, 2025

Pharmaceutical company Collegium Pharmaceutical (NASDAQ:COLL) will be reporting earnings this Thursday morning. Here’s what you need to know.

Via StockStory

Topics Government World Trade

1 Cash-Producing Stock to Own for Decades and 2 We Ignore

August 04, 2025

While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak...

Via StockStory

5 Hot Stocks With Summer Buybacks You Can Cash In On ↗

July 10, 2025

The five stocks on this list issued aggressive buyback authorizations in June or July and have the power to follow through with their plans.

Via MarketBeat

1 Safe-and-Steady Stock to Keep an Eye On and 2 to Be Wary Of

July 08, 2025

Low-volatility stocks may offer stability, but that often comes at the cost of slower growth and the upside potential of more dynamic companies.

Via StockStory

1 Russell 2000 Stock on Our Watchlist and 2 to Keep Off Your Radar

June 17, 2025

The Russell 2000 (^RUT) is packed with potential breakout stocks, thanks to its focus on smaller companies with high growth potential. However, smaller size also means these businesses often lack the...

Via StockStory

COLL Q1 Earnings Call: ADHD Portfolio Drives Growth, Management Details Capital Deployment Priorities

June 10, 2025

Pharmaceutical company Collegium Pharmaceutical (NASDAQ:COLL) reported Q1 CY2025 results topping the market’s revenue expectations, with sales up 22.7% year on year to $177.8 million. The company...

Via StockStory

3 of Wall Street’s Favorite Stocks with Mounting Challenges

June 10, 2025

Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional...

Via StockStory

Branded Pharmaceuticals Stocks Q1 In Review: Collegium Pharmaceutical (NASDAQ:COLL) Vs Peers

June 05, 2025

As the Q1 earnings season wraps, let’s dig into this quarter’s best and worst performers in the branded pharmaceuticals industry, including Collegium Pharmaceutical (NASDAQ:COLL) and its peers.

Via StockStory

Topics Artificial Intelligence Intellectual Property

1 Stock Under $50 with Exciting Potential and 2 to Turn Down

June 04, 2025

Via StockStory

3 Small-Cap Stocks Facing Headwinds

May 15, 2025

Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that these businesses have increased downside...

Via StockStory

Collegium Pharmaceutical (NASDAQ:COLL) Exceeds Q1 Expectations

May 08, 2025

Via StockStory

Collegium Pharmaceutical (COLL) Q1 Earnings: What To Expect

May 07, 2025

Pharmaceutical company Collegium Pharmaceutical (NASDAQ:COLL) will be reporting earnings tomorrow after market close. Here’s what to look for.

Via StockStory

3 Healthcare Stocks That Concern Us

April 28, 2025

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Despite the rosy long-term prospects, short-term headwinds such as COVID...

Via StockStory

Topics Stocks

2 Reasons to Watch COLL and 1 to Stay Cautious

April 14, 2025

Collegium Pharmaceutical’s stock price has taken a beating over the past six months, shedding 31.6% of its value and falling to $26.01 per share. This might have investors contemplating their next...

Via StockStory

What Analysts Are Saying About Collegium Pharmaceutical Stock ↗

April 09, 2025

Via Benzinga

A Look Back at Branded Pharmaceuticals Stocks’ Q4 Earnings: Collegium Pharmaceutical (NASDAQ:COLL) Vs The Rest Of The Pack

April 02, 2025

The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Collegium Pharmaceutical...

Via StockStory

Topics Artificial Intelligence Intellectual Property

Forecasting The Future: 4 Analyst Projections For Collegium Pharmaceutical ↗

March 24, 2025

Via Benzinga

Q4 Earnings Highs And Lows: Royalty Pharma (NASDAQ:RPRX) Vs The Rest Of The Branded Pharmaceuticals Stocks

March 21, 2025

The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Royalty Pharma (NASDAQ:RPRX)...

Via StockStory

Topics Artificial Intelligence Intellectual Property

Collegium Pharmaceutical’s (NASDAQ:COLL) Q4 Sales Top Estimates, Stock Jumps 14.1%

February 27, 2025

Pharmaceutical company Collegium Pharmaceutical (NASDAQ:COLL) reported Q4 CY2024 results topping the market’s revenue expectations, with sales up 21.5% year on year to $181.9 million. The company...

Via StockStory

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Collegium Pharmaceutical, Inc. - Common Stock (NQ:COLL)

Headline News about Collegium Pharmaceutical, Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today